Release Details

A scientist inside the laboratory testing specimens

Statement: Biogen Shares Update on Angelman Syndrome Program

May 16, 2024
May 16, 2024 – In addition to discontinuing development of BIIB105, an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS), Biogen has elected not to exercise its option to license and lead development of BIIB121, an ASO designed to restore expression of ubiquitin-protein in patients with Angelman syndrome. 
Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon